Roivant Sciences Ltd. (ROIV)
Nasdaq: ROIV · Pharmaceutical Preparations · London · filing with the SEC since 2015
Grade5.3
◀ Past 6.1● Present 6.5▶ Future 3.6
Filings
303 filings since 2017 beside 703 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-Q
Quarterly report for the quarter ending Dec 31, 2026Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by Feb 9, 2027
10-K
Annual report for the fiscal year ending Mar 31, 2027Large accelerated filers have 60 days after the fiscal year ends.
by May 30, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 40 days after the quarter ended. The proxy statement was last filed Jul 29, 2026.
Filings a yearinsider forms included
351070128257155171162
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 2 times in the last 36 months, the newest Mar 20, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Apr 2, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Mar 3, 2026
8-K items 1.01, 7.01, 8.01, 9.01
Major agreement signed; Investor disclosure (Regulation FD); Other event · Current report
40 of 303 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.